

30th July, 2020

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended $30^{\rm th}$ June, 2020

The presentation on unaudited Consolidated Financial Results for the quarter ended 30th June, 2020 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL VP (LEGAL) & COMPANY SECRETARY

Encl: A/a



Q1 FY 2020-21

Revenues: Summary



Revenue: Summary

Revenues (Rs crores)	Q1 20-21	Q1 19-20	Gr%
India	925	907	2%
United States	373	376	-1%
Brazil	140	174	-20%
Germany	246	262	-6%
Other countries	234	176	33%
Others (Inc. CRAMS)	138	127	9%
Total	2,056	2,022	2%

